Weight Loss Results
Wegovy Before and After Results
Quick Answer: Clinical trial data shows patients on Wegovy (semaglutide 7.2 mg) lose an average of 6–8% of body weight within the first three months, around 12% by six months and approximately 19–21% by 72 weeks. In absolute terms, a patient starting at 112 kg could expect to lose 7–9 kg in three months, 13 kg by six months and up to 23 kg within 72 weeks. Results vary depending on starting weight, adherence, diet and activity level.~19–21%average weight loss at 72 weeks (STEP UP trial)
~6–8%typical weight loss at 3 months
9 in 10patients lost ≥5% of body weight (STEP UP)
STEP UP Trial Data
Clinical Trial Results — Semaglutide 7.2 mg
The STEP UP phase 3b trial enrolled adults with BMI ≥30 (or ≥27 with a weight-related comorbidity) for 72 weeks. Participants received semaglutide 7.2 mg once weekly or placebo alongside a reduced-calorie diet and increased physical activity.
| Outcome Measure | Semaglutide 7.2 mg | Placebo |
|---|---|---|
| Mean weight loss at 72 weeks | 20.7% | 2.4% |
| Weight loss of ≥5% | 9 in 10 participants | 32% of participants |
| Weight loss of ≥10% | 69% of participants | 12% of participants |
| Weight loss of ≥15% | 50% of participants | 5% of participants |
| Weight loss of ≥20% | 32% of participants | 2% of participants |
| Mean absolute weight reduction | ~23.2 kg | ~2.7 kg |
Weight Loss by Starting Weight
Expected Results by Starting Weight
The following examples are based on STEP UP trial averages. Individual results will vary based on starting weight, metabolic health, diet quality, activity level and adherence.
| Starting Weight | 3 Months (~7%) | 6 Months (~12%) | 72 Weeks (~20%) |
|---|---|---|---|
| 80 kg | ~6 kg → 74 kg | ~10 kg → 70 kg | ~16 kg → 64 kg |
| 100 kg | ~7 kg → 93 kg | ~12 kg → 88 kg | ~20 kg → 80 kg |
| 120 kg | ~8 kg → 112 kg | ~14 kg → 106 kg | ~24 kg → 96 kg |
| 140 kg | ~10 kg → 130 kg | ~17 kg → 123 kg | ~28 kg → 112 kg |
Wegovy begins working within the first week, but significant weight loss is gradual and cumulative. The most dramatic results emerge between months 3 and 12 as the dose reaches and sustains the maintenance level. Wegovy 7.2 mg is not a rapid weight loss solution — it is a long-term treatment that produces meaningful, sustained results when used consistently.
FAQs
Frequently Asked Questions
STEP UP data shows average weight loss of approximately 20.7% of body weight over 72 weeks on semaglutide 7.2 mg — approximately 21 kg for a 100 kg patient over 18 months. More than 9 in 10 patients lost 5% or more; approximately 1 in 3 lost 25% or more.
At three months, most Wegovy patients have lost between 5% and 8% of their starting body weight. For someone starting at 100 kg this means approximately 5–8 kg. Patients who have made dietary improvements alongside treatment tend to see results at the higher end of this range.
Wegovy begins producing biological effects within the first week of injection. Most patients notice a reduction in appetite within two to three weeks. However, significant weight loss is gradual — the average patient loses 2–4 kg in the first month and around 6–8% by three months.
Yes — a 5% reduction from baseline is a clinically meaningful threshold associated with measurable improvements in blood pressure, blood glucose and cardiovascular risk markers. Achieving 5% loss by month three is consistent with clinical trial averages.
The STEP 4 trial demonstrated that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within 12 months. This highlights that Wegovy is most effective as a long-term intervention.
Exercise significantly improves body composition outcomes — particularly resistance training, which helps preserve lean muscle mass. It has a modest additional impact on total weight lost but a meaningful impact on long-term metabolic health.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Wharton S et al. STEP UP. Lancet Diabetes Endocrinol. 2025. Wilding JPH et al. STEP 1. N Engl J Med. 2021. NICE TA875. 2023. Novo Nordisk. Wegovy SmPC. 2023/2025. Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not medical advice.